{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:45:09Z","timestamp":1787589909200,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy marked by increased left ventricular wall thickness, leading in some cases to left ventricular outflow tract (LVOT) obstruction, heart failure, and arrhythmias. Mavacamten, a selective allosteric inhibitor of cardiac myosin, has demonstrated benefits in improving hemodynamics and reducing LVOT obstruction. However, its impact on arrhythmic burden remains unclear, with reports of early atrial fibrillation (AF) risk contrasting with long-term reductions in arrhythmias. This study assesses the temporal patterns of Holter-detected arrhythmias in HCM patients treated with mavacamten. Methods: This retrospective study included HCM patients from three Mayo Clinic sites. Baseline demographic, clinical, and echocardiographic data were collected. Holter monitoring was performed at baseline, short-term (&lt;6 months), and long-term (&gt;6 months) follow-up. Arrhythmic events, including premature atrial contractions (PACs), premature ventricular contractions (PVCs), and supraventricular tachycardia (SVT), were analyzed using standardized rates per 24 h. Statistical comparisons utilized the Wilcoxon signed-rank test. Results: Twenty-seven patients (56% female, median age 66 years) were included. PACs, PVCs, and SVT duration transiently but not significantly increased at short-term follow-up but returned to baseline at long-term follow-up. No sustained or high-risk ventricular arrhythmias were observed. Conclusions: Mavacamten is associated with transient arrhythmic fluctuations early in treatment, followed by stabilization. These findings support its long-term electrophysiological safety and underscore the need for early rhythm monitoring. Further research should explore its role in arrhythmic risk stratification in HCM patients.<\/jats:p>","DOI":"10.3390\/biomedicines13041005","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T20:38:26Z","timestamp":1745267906000},"page":"1005","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Temporal Patterns of Holter-Detected Arrhythmias in Hypertrophic Cardiomyopathy Patients Treated with Mavacamten"],"prefix":"10.3390","volume":"13","author":[{"given":"Amro","family":"Badr","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6908-8608","authenticated-orcid":false,"given":"Kaitlin","family":"Roehl","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Suppah","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humam","family":"Abo Abdullah","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-4286","authenticated-orcid":false,"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C.","family":"Siontis","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-0920","authenticated-orcid":false,"given":"Steve R.","family":"Ommen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Giudicessi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7880","authenticated-orcid":false,"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.15420\/usc.2023.21","article-title":"Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures","volume":"18","author":"Banthiya","year":"2024","journal-title":"US Cardiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"key":"ref_3","first-page":"e558","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2004.11.043","article-title":"Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy","volume":"45","author":"Adabag","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvac054","article-title":"Frequent premature atrial contractions as a signalling marker of atrial cardiomyopathy, incident atrial fibrillation, and stroke","volume":"119","author":"Farinha","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_7","first-page":"e21101","article-title":"Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review","volume":"14","author":"Palyam","year":"2022","journal-title":"Cureus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.jacadv.2024.101210","article-title":"Atrial Fibrillation in Hypertrophic Cardiomyopathy","volume":"3","author":"Saberi","year":"2024","journal-title":"JACC Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13019-023-02299-x","article-title":"Prognostic effect of atrial fibrillation on survival in patients with hypertrophic cardiomyopathy: A meta-analysis","volume":"18","author":"Du","year":"2023","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_10","first-page":"22","article-title":"Frequent ventricular extrasystoles: Significance, prognosis and treatment","volume":"9","author":"Merino","year":"2011","journal-title":"E-J. Cardiol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shen, H., Dong, S.Y., Ren, M.S., and Wang, R. (2022). Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.949294"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ye, Y., Ji, Z., Zhou, W., Pu, C., Li, Y., Zhou, C., Hu, X., Chen, C., Sun, Y., and Huang, Q. (2021). Mean Scar Entropy by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Associated with Ventricular Arrhythmias Events in Hypertrophic Cardiomyopathy. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.758635"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2016.09.017","article-title":"Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy","volume":"5","author":"Anguera","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/clc.23445","article-title":"Burden of premature ventricular contractions beyond nonsustained ventricular tachycardia is related to the myocardial extracellular space expansion in patients with hypertrophic-cardiomyopathy","volume":"43","author":"Chung","year":"2020","journal-title":"Clin. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","article-title":"Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside","volume":"82","author":"Palandri","year":"2022","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"\u03b2 Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.hjc.2022.11.002","article-title":"Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy","volume":"70","author":"Gartzonikas","year":"2023","journal-title":"Hell. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wo\u0142owiec, \u0141., Grze\u015bk, G., Osiak, J., Wijata, A., M\u0119dlewska, M., Gaborek, P., Banach, J., Wo\u0142owiec, A., and G\u0142owacka, M. (2022). Beta-blockers in cardiac arrhythmias-Clinical pharmacologist\u2019s point of view. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1043714"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1161\/CIRCULATIONAHA.123.065017","article-title":"Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy with Non\u2013\u03b2-Blocking R-Enantiomer Carvedilol","volume":"148","author":"Seo","year":"2023","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10557-022-07334-y","article-title":"An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps","volume":"37","author":"Triska","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/CIRCRESAHA.118.314202","article-title":"Identifying the Transcriptome Signatures of Calcium Channel Blockers in Human Induced Pluripotent Stem Cell\u2013Derived Cardiomyocytes","volume":"125","author":"Lam","year":"2019","journal-title":"Circ. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/phar.1664","article-title":"Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug","volume":"35","author":"Verlinden","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacbts.2019.06.004","article-title":"Electrophysiological and Contractile Effects of Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy: A Translational Study","volume":"4","author":"Coppini","year":"2019","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in Patients with Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results from the VALOR-HCM Randomized Clinical Trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): Health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e014986","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin Inhibition and Left Ventricular Diastolic Function in Patients with Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights from the VALOR-HCM Study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients with Obstructive Hypertrophic Cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM","volume":"18","author":"Okushi","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_33","first-page":"e011188","article-title":"Long-Term Effects of Mavacamten on Electromechanical Dispersion and Deformation in Obstructive Hypertrophic Cardiomyopathy","volume":"17","author":"Palinkas","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten","volume":"21","author":"Castrichini","year":"2024","journal-title":"Heart Rhythm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.echo.2024.01.009","article-title":"Effect of Mavacamten on Hypertrophic Cardiomyopathy Patients with Left Ventricular Outflow Tract Obstruction Provoked Only Postexercise or with Amyl Nitrite","volume":"37","author":"Roehl","year":"2024","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mcpdig.2024.04.002","article-title":"Assessment of Positive Cardiac Remodeling in Hypertrophic Obstructive Cardiomyopathy Using an Artificial Intelligence\u2013Based Electrocardiographic Platform in Patients Treated with Mavacamten","volume":"2","author":"Suppah","year":"2024","journal-title":"Mayo Clin. Proc. Digit. Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e009796","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Margara, F., Psaras, Y., Wang, Z.J., Schmid, M., Doste, R., Garfinkel, A.C., Repetti, G.G., Seidman, J.G., Seidman, C.E., and Rodriguez, B. (2022). Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-26889-2"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.echo.2024.10.001","article-title":"Sustained Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy: Long-Term Assessment Using Artificial Intelligence-Electrocardiogram and Echocardiographic Data","volume":"38","author":"Suppah","year":"2025","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results from the MAVA-LTE Study, EXPLORER-LTE Cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/4\/1005\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:49Z","timestamp":1760030329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/4\/1005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["biomedicines13041005"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13041005","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}